The company's latest presentation supports the idea that its lead program will make billions.

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

It was supposed to be a routine Stone Age settlement excavation to clear a path for a new roundabout and water pipes near ...

Viking Holdings plans to report third quarter financial results ... She has been the cruise columnist for AFAR.com, and her freelance stories have appeared in a wide range of publications, from The ...

What if, however, you didn’t have to fuss with finicky hacks or wash extra loads of laundry at all? Thanks to luxury kitchen ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

Viking Therapeutics shares surge as VK2735 shows significant ... At the same time, the forecast for gross fee revenues was ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

The Valley City State University women’s basketball team suffered its first defeat of the season after an 86-51 loss to Briar ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

The Viking Press has become a cult favorite among fitness enthusiasts, especially those aiming to develop powerful and ...